Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England

The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50–89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose...

Descripción completa

Detalles Bibliográficos
Autores principales: Amirthalingam, Gayatri, Bernal, Jamie Lopez, Andrews, Nick J., Whitaker, Heather, Gower, Charlotte, Stowe, Julia, Tessier, Elise, Subbarao, Sathyavani, Ireland, Georgina, Baawuah, Frances, Linley, Ezra, Warrener, Lenesha, O’Brien, Michelle, Whillock, Corinne, Moss, Paul, Ladhani, Shamez N., Brown, Kevin E., Ramsay, Mary E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664823/
https://www.ncbi.nlm.nih.gov/pubmed/34893611
http://dx.doi.org/10.1038/s41467-021-27410-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664823/
https://www.ncbi.nlm.nih.gov/pubmed/34893611
http://dx.doi.org/10.1038/s41467-021-27410-5

Ejemplares similares